Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11883060 | 1.00 | MAPT (0.44) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL2760377 | 0.95 | MAPT (0.39) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL9366064 | 0.85 | MAPT (0.37) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL12864195 | 0.82 | SGMS1 (0.31) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL11539159 | 0.82 | MAPT (0.34) | MAPTCA12GMNNALDH1A1CA1 | |
| Methacrylic Acid SCHEMBL27075333 | 0.81 | NPC1 (0.35) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL26708757 | 0.80 | MAPT (0.37) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL25497613 | 0.78 | — | — | |
| SCHEMBL30428269 | 0.78 | — | — | |
| SCHEMBL9836353 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-7915237-B2 | Viricides against herpes virus; autoimmune disease; antitumor agents | LUMAVITA AG (CH) | 2011-03-29 | — | — | US | claimed |
| US-20060116535-A1 | Method of deuteration | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-01 | — | — | US | claimed |
| EP-1577280-A1 | METHOD OF DEUTERIZATION | Wako Pure Chemical Industries, Ltd. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050085448-A1 | Production of pure stereoisomers of tricyclo[5.2.1.0 2.6]-dec-9-yl-xanthogenate and medicaments therefrom | LUMAVITA AG (CH) | 2005-04-21 | — | — | US | claimed |
| EP-1443921-B1 | PRODUCTION OF PURE STEREOISOMERS OF TRICYCLO-[5.2.1.0(2.6)]-DEC-9-YL-XANTHATE ESTERS AND THEIR USE AS MEDICAMENTS | BIOSPHINGS AG (DE) | 2005-04-20 | — | — | EP | claimed |
| EP-0589341-B1 | Process for the preparation von endo/exo-8-N,N-dialkylaminoexo-tricyclo(5.2.1.0 2,6) decane | HOECHST AG (DE) | 1997-01-02 | — | — | EP | claimed |
| JP-6025040-A | — | — | None | — | — | JP | disclosed |
| JP-8245435-A | — | — | None | — | — | JP | disclosed |
| US-12013523-B2 | Immersion oils having long service life | CARL ZEISS JENA GMBH (DE) | 2024-06-18 | — | — | US | disclosed |
| US-20240094519-A1 | ACETALS OF TRICYCLODECANE ALCOHOLS AS IMMERSION LIQUID MEDIA | CARL ZEISS JENA GMBH (DE) | 2024-03-21 | — | — | US | disclosed |
| WO-2024018984-A1 | COPOLYMER, CURABLE RESIN COMPOSITION, AND CURED ARTICLE | 株式会社ダイセル | 2024-01-25 | — | — | WO | disclosed |
| US-20230350296-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-4318863-A | CARBONATE ESTERS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0039232-A1 | Substituted tricyclodecane derivatives, processes for preparing such derivatives, processes for using such derivatives and compositions using such derivatives | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-11-04 | — | — | EP | disclosed |
| US-4275251-A | SYNTHETIC ADDITIVE FOR FLAVORING AND PERFUMES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4169953-A | VIRICIDES | KAO SOAP CO., LTD. (JP) | 1979-10-02 | — | — | US | disclosed |
| US-4120906-A | 1-Halogenotricyclo [4.3.1.12,5 ] undecane and process for the preparation thereof | KAO SOAP CO., LTD. (JP) | 1978-10-17 | — | — | US | disclosed |
| US-4111990-A | 1-Acetylaminotricyclo [4.3.1.12,5 ] undecane and process for the preparation thereof | KAO SOAP CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-3976712-A | 2,4-Exo-ethanobicyclo (3.3.1)nonane | KAO SOAP CO., LTD. (JA) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12013523-B2 | Immersion oils having long service life | DGKI, CCNE2, CYCS | MAPT 4048/4885CA12 1119/4885GMNN 3627/4885 |
| US-20050085448-A1 | Production of pure stereoisomers of tricyclo[5.2.1.0 2.6]-dec-9-yl-xanthogenate and medicaments therefrom | EXOSC5, GALE, HK2 | MAPT 4293/4885CA12 1117/4885GMNN 4383/4885 |
| US-20060116535-A1 | Method of deuteration | ARL1, IDH2, IDH3A | MAPT 4851/4885CA12 512/4885GMNN 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.